Deadline: 21-Nov-24
Pfizer is pleased to announce the Competitive Grant Program to Educate Patients and Caregivers Living with Bladder Cancer from Non-Muscle Invasive Bladder Cancer (NMIBC) to Locally Advanced or Metastatic Urothelial Carcinoma.
General Area of Interest
- Projects that will be considered for Pfizer independent grant support will educate patients or caregivers in one or more of the following example areas:
- provide accurate information about bladder cancer, its causes, risk factors, diagnosis, staging, treatment options, risks of recurrence or progression, and prognosis.
- empower patients to make informed decisions about their care and participate actively in their treatment planning and management.
- facilitate communication and collaboration among patients, caregivers, and multi-disciplinary health care providers.
- help patients understand what their treatment journey might look like, including when they might need systemic therapy from a urologist or medical oncologist.
- explain the benefits and risks of different types of therapies, such as radical cystectomy, urinary diversion, intravesical therapy, chemotherapy, radiation therapy, and targeted systemic therapy.
- promote adherence to treatment and enhance patient follow-up based on treating physician recommendations
- support the identification, prevention and/or management of potential disease complications and treatment side effects.
- Examples of educational formats that will be considered under this RFP include but are not limited to:
- Live in-person or virtual live or asynchronous educational sessions
- Online articles, newsletter articles, training courses, webinars
- Social media posted & linked content
- Videos, podcasts, infographics, animations
Funding Information
- Individual projects requesting up to $150,000 will be considered. The estimated total available budget related to this RFP is $500,000.
Target Audience
- Patients and caregivers; patient/nurse navigators – to include patients with any bladder cancer stage from Non-Muscle Invasive Bladder Cancer (NMIBC) to Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC).
Eligibility Criteria
- Geographic Scope: United States (projects with global reach beyond the US are also in-scope)
- Applicant organizations to this RFP must be based in the United States
- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; patient advocacy groups and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or physician-owned medical practices.
- If the project involves multiple departments within an institution and/or between different institutions/organizations/associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
For more information, visit Pfizer.
